{"filings":[{"id":77965,"accession_number":"0001493152-26-022877","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2026-05-14T12:05:15+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics Q1 2026: Processed 3,177 EsoGuard tests, revenue $1.3M, net loss $23.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Processed 3,177 EsoGuard tests in Q1, generating $1.3M in revenue; operating expenses $13.4M including $1.4M stock comp.","GAAP net loss attributable to common stockholders $23.6M ($0.17 per share); non-GAAP adjusted loss $10.5M ($0.07 per share).","Ended Q1 with $27.9M cash; proforma cash $45M after $17M public offering, extending runway into 2027.","Expects Medicare coverage as key milestone; preview of upcoming guideline update recommending EsoGuard as only non-endoscopic test."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":1256000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95531,"accession_number":"0001493152-26-018926","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lucid Diagnostics closes $18M underwritten offering of 18M shares at $1.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sale of 18,000,000 shares at $1.00/share; gross proceeds $18M, net proceeds ~$16.8M.","Net proceeds to be used for working capital and general corporate purposes.","Joint bookrunners: Canaccord Genuity LLC and BTIG, LLC.","Offering anchored by $15M investment from fundamental institutional investor and support from a large existing shareholder.","Offered under effective shelf registration statement on Form S-3 declared effective March 26, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95530,"accession_number":"0001493152-26-018725","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics prices $18M underwritten offering of 18M shares at $1.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 18,000,000 common shares at $1.00 each; gross proceeds ~$18M.","Underwriters purchase at $0.94/share; net proceeds for working capital and general corporate purposes.","Anchored by a $15M investment from a fundamental institutional investor and support from a large existing shareholder.","Closing expected on or about April 24, 2026, subject to customary conditions.","Canaccord Genuity and BTIG act as joint bookrunners; shelf registration effective March 26, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108670,"accession_number":"0001493152-26-012807","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics Q4 2025 revenue $1.5M, net loss $16.3M; VA contract awarded","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 EsoGuard tests 3,664; revenue $1.5M; GAAP net loss $16.3M ($0.12/share); non-GAAP adj. loss $12.6M ($0.10/share).","Cash $34.7M at Dec 31, 2025 vs $22.4M at Dec 31, 2024; operating expenses $15.5M incl $1.2M stock-based comp.","Awarded U.S. Department of Veterans Affairs contract for EsoGuard with $1,938 Medicare-aligned pricing across 170 VA medical centers.","Largest real-world esophageal precancer detection study (nearly 12,000 patients) shows EsoCheck 95% technical success rate and 95% procedures under two minutes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125118,"accession_number":"0001493152-25-021748","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics Q3 revenue $1.2M, loss $0.10/share; key Medicare coverage step from unanimous CAC expert support","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Processed 2,841 EsoGuard tests in Q3 2025, revenue $1.2 million.","GAAP net loss $10.4M ($0.10/share); non-GAAP adjusted loss $10.3M ($0.10/share).","Cash $47.3M after $27M public offering; runway extended through 2026.","MolDx CAC meeting on Sept 4: medical experts unanimously supported Medicare coverage for EsoGuard.","Appointed Danielle Scelfo as SVP Market Access to lead payor engagement and coverage expansion."],"consensus_eps_estimate":-0.1124,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":3202000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141829,"accession_number":"0001493152-25-014872","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-09-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics appoints John R. Palumbo, healthcare veteran, to board effective Sept 22, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John R. Palumbo appointed as Class B director, effective September 22, 2025, designated by convertible note holders.","Palumbo brings 40 years of healthcare leadership, including roles at AmerisourceBergen, Allscripts, and ValueHealth.","He will receive cash fees and equity awards per non-employee director compensation policy.","He currently serves on boards of PM Pediatrics, ivWatch, Qless, and chairs Brado advisory board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141828,"accession_number":"0001493152-25-013046","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-09-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lucid Diagnostics closes $28.75M public offering of 28.75M shares at $1.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten public offering of 28,750,000 shares at $1.00 per share, including full exercise of underwriters' option for 3,750,000 additional shares.","Net proceeds expected to be approximately $26.9 million after deducting underwriting discounts and offering expenses.","Proceeds will be used for working capital and general corporate purposes.","Canaccord Genuity and BTIG acted as joint bookrunners; Maxim Group LLC served as co-manager.","Offering made under existing effective shelf registration statement (Form S-3, File No. 333-268560)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141827,"accession_number":"0001493152-25-012962","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-09-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics prices $25M public offering of 25M shares at $1.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced 25,000,000 shares of common stock at $1.00 per share; gross proceeds ~$25M before expenses.","Underwriters granted 30-day option to purchase up to additional 3,750,000 shares at the same price.","Net proceeds to be used for working capital and general corporate purposes; closing expected Sept 11, 2025.","Canaccord Genuity and BTIG are joint bookrunners; Maxim Group is co-manager.","Offering made under effective shelf registration statement S-3 (No. 333-268560)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141826,"accession_number":"0001493152-25-011882","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics Q2 2025 revenue $1.2M; net loss $7.9M; cash $31.1M after offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Processed 2,756 EsoGuard tests in Q2 2025; revenue $1.2 million.","GAAP net loss $7.9M ($0.08 EPS); non-GAAP adjusted loss $9.9M ($0.10 EPS).","Ended Q2 with $31.1M cash after $16.1M public offering; runway extended into 2026.","Medicare contractor advisory committee meeting scheduled September 4 for EsoGuard coverage.","Partnered with Hoag for esophageal precancer testing; joined Russell 2000/3000 indexes."],"consensus_eps_estimate":-0.1234,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":1991000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159749,"accession_number":"0001641172-25-015613","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Lucid Diagnostics shareholders re-elect Lapidus and Sokolov, approve stock issuance, ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["70.9% of shares represented at June 18 annual meeting; all management proposals passed.","Class A directors Stanley N. Lapidus and Jacque J. Sokolov re-elected with ~63.8M votes each.","Issuance of shares under 2024 Convertible Notes approved: 69.6M for, 0.62M against.","Ratification of CBIZ CPAs P.C. as auditor for FY2025: 90.0M for, 0.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159748,"accession_number":"0001641172-25-013059","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Lucid Diagnostics enters $25M ATM equity offering with Maxim Group","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $25M of common stock may be sold at-the-market via Maxim Group as agent.","Agent commission set at 3% of gross proceeds; $60k legal fee reimbursement at signing.","Proceeds to be used for working capital and general corporate purposes.","Agreement dated May 30, 2025; offering under effective Form S-3 (File No. 333-268560).","Company may terminate agreement at any time with ten business days' notice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159747,"accession_number":"0001641172-25-010101","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics Q1 2025 revenue $0.8M, net loss $36M; raises ~$46.7M in equity","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $0.8M from 3,034 EsoGuard tests; GAAP net loss $36.0M ($0.52/share); adjusted loss $11.2M ($0.16/share).","Ended Q1 with $25.2M cash; subsequent public offering netted $16.1M; combined with earlier offerings total ~$46.7M raised.","Partnered with major health system for EsoGuard testing; NCI study supports expanded indication without GERD, increasing market 70%.","Cash-pay and employer channels expected to start contractually-guaranteed revenue in 2H25.","Proforma cash over $40M at Q1 end; runway extended past key Medicare and other reimbursement milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":828000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159746,"accession_number":"0001641172-25-006239","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Lucid Diagnostics changes auditor to CBIZ CPAs after Marcum acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as auditor on April 23, 2025; CBIZ CPAs engaged same day with audit committee approval.","No disagreements or reportable events with Marcum during fiscal years 2024 and 2023 through resignation.","Marcum's audit reports for 2024 and 2023 included a going concern explanatory paragraph.","Marcum's acquisition by CBIZ CPAs on Nov 1, 2024 triggered the change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159745,"accession_number":"0001641172-25-003740","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-04-11T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lucid Diagnostics closes $16.1M public offering of 14.4M shares at $1.20/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed sale of 14,375,000 shares of common stock at $1.20/share; underwriters' option exercised in full.","Net proceeds expected to be approximately $16.1 million after underwriting discounts and expenses.","Proceeds to be used for working capital and general corporate purposes.","Canaccord Genuity acted as sole bookrunner; Maxim Group as co-manager of the offering.","Offering made under existing shelf registration statement S-3 effective Dec 6, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159744,"accession_number":"0001641172-25-003526","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics prices $15M public offering of 12.5M shares at $1.20 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$15M from 12.5M shares at $1.20; underwriters have 45-day option for 1.875M additional shares.","Closing expected April 11, 2025; net proceeds for working capital and general corporate purposes.","Canaccord Genuity sole bookrunner, Maxim Group co-manager; offered under shelf registration effective Dec 2022.","Offering significantly dilutes existing shareholders; exact dilution depends on option exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178124,"accession_number":"0001641172-25-000514","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics reports Q4 EsoGuard revenue $1.2M, record 4,042 tests processed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record 4,042 EsoGuard tests processed in Q4 2024, up 45% sequentially and 84% year-over-year.","EsoGuard revenue of $1.2M for Q4; GAAP net loss $11.5M ($0.20/share); non-GAAP loss $10.9M ($0.19/share).","Cash and equivalents $22.4M at Dec 31, 2024; pro forma ~$36.9M after Q1 2025 common stock financing.","Secured first commercial coverage from Highmark and first state biomarker agreement with Blue Cross Blue Shield of RI.","Completed $22M convertible debt refinancing and $15.3M stock financing, net proceeds $32.8M, extending cash runway."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178123,"accession_number":"0001493152-25-009231","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Lucid Diagnostics closes $15.3M registered direct offering of 13.9M shares at $1.10/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed offering of 13,939,331 common shares at $1.10 per share for gross proceeds of $15.3M.","Net proceeds after fees and expenses estimated at $14.5M; Canaccord Genuity acted as sole placement agent.","Funds to be used for working capital and other general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178122,"accession_number":"0001493152-25-008980","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics raises $15.3M in registered direct offering of 13.9M shares at $1.10/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$15.3M from sale of 13,939,331 shares at $1.10/share; net proceeds ~$14.5M after fees/expenses.","Offering expected to close on March 5, 2025; Canaccord Genuity acting as sole placement agent.","Proceeds to be used for working capital and general corporate purposes; offering made under effective Form S-3 shelf."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178121,"accession_number":"0001493152-25-008974","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lucid Diagnostics terminates ATM equity offering program after minimal sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated ATM prospectus supplement effective March 4, 2025; no new sales without new filing.","Only $292,790 raised from 230,068 shares under the $6.5M facility since December 2022.","Sales Agreement with Cantor Fitzgerald remains in force but ATM sales are suspended."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178120,"accession_number":"0001493152-25-008100","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lucid Diagnostics regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notification on Feb 24, 2025 confirming compliance with $1 minimum bid price rule.","Closing bid price was $1 or greater for 11 consecutive trading days from Feb 7 to Feb 21, 2025.","Company had been non-compliant since June 2024 and received a 180-day extension through June 16, 2025.","Compliance regained under Nasdaq Listing Rule 5550(a)(2); delisting risk removed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194792,"accession_number":"0001493152-24-051061","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lucid Diagnostics receives Nasdaq extension until June 16, 2025 to regain bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Received Nasdaq letter granting additional 180 days (to June 16, 2025) to meet $1 minimum bid price.","Initial 180-day compliance period ended Dec 18, 2024 without regaining compliance.","To regain compliance, closing bid price must be at least $1 for ten consecutive business days.","Stock continues trading on Nasdaq under LUCD; no immediate delisting effect.","Company intends to consider all available options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194791,"accession_number":"0001493152-24-048170","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-11-29T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","3.03","9.01"],"status":"ready","headline":"Lucid Diagnostics closes $21.95M senior secured convertible notes private placement; repays 2023 note","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Sold $21.95M principal amount Senior Secured Convertible Notes, net proceeds $18.3M after repaying 2023 note.","Used ~$3.6M to redeem 2023 Convertible Note (7.875% interest, $5 conversion price) with ~$2.7M outstanding principal.","Notes secured by substantially all assets; subsidiaries guarantee obligations.","Company granted registration rights for underlying common shares; must file resale statement within 120 days.","Notes convertible into common stock; terms per November 12, 2024 filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194790,"accession_number":"0001493152-24-046587","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-11-18T23:59:59+00:00","items":["1.01","2.03","3.02","3.03","9.01"],"status":"ready","headline":"Lucid Diagnostics sells $21.75M in convertible notes to redeem existing 2023 note","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["Aggregate $21.75M in Senior Secured Convertible Notes sold to accredited investors.","Proceeds will redeem the 2023 Senior Convertible Note at the optional redemption price.","Issuance and redemption expected within 10–20 business days of November 8, 2024.","Notes and conversion shares issued under Section 4(a)(2) exemption from registration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194789,"accession_number":"0001493152-24-044974","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics Q3: EsoGuard rev $1.2M (+50% YoY), net loss $12.4M ($0.25/share), raises $21.75M via notes","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["EsoGuard revenue $1.2M, up 20% sequentially from Q2 2024 and 50% YoY from Q3 2023.","GAAP net loss attributable to common stockholders $12.4M, or $(0.25) per share.","Non-GAAP adjusted loss $10.1M, or $(0.20) per share, excluding stock-based comp and other non-cash items.","Cash $14.5M at Sep 30, 2024; entered into $21.75M senior secured convertible notes to extend cash runway.","Performed 2,787 commercial EsoGuard tests in Q3; October record >1,400 tests; clinical validation study accepted."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":3149000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194788,"accession_number":"0001493152-24-044502","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","3.03","9.01"],"status":"ready","headline":"Lucid Diagnostics redeems 2023 convertible note, issues $1.00/sh 12% secured notes due 2029","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Notice to redeem 2023 Senior Convertible Note at optional redemption price; payment due within 10-20 business days.","Enters Securities Purchase Agreement for 2024 Senior Secured Convertible Notes with 12% annual interest, 5-year maturity.","Notes convertible at $1.00/share; secured by all company assets; financial covenant requires minimum $5M cash.","Event of default if no positive Medicare coverage decision for EsoGuard by 18-month anniversary of issuance.","PAVmed agrees not to sell LUCD shares for six months from closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211086,"accession_number":"0001493152-24-031161","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics Q2 2024: EsoGuard test volume +31% QoQ to record 3,147; revenue $1.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["EsoGuard volume 3,147 (record), up 31% sequentially and 44% YoY; revenue $1.0M flat QoQ but +514% YoY.","GAAP net loss $11.0M ($0.23/share); non-GAAP adjusted loss $9.7M ($0.20/share).","Positive clinical data: ENVET-BE study shows 2.4x increased yield; BE-1 study 88% sensitivity, 99% NPV.","Cash $24.9M after $11.6M Series B-1 preferred stock issuance; held CMS MAC Palmetto GBA MolDX meeting.","First major #CheckYourFoodTube event with upfront contracted payment; revenue cycle management improving."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1977000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211085,"accession_number":"0001493152-24-028854","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Lucid Diagnostics shareholders approve increase in authorized shares, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders re-elected Dr. Lishan Aklog, Debra White, and Dennis Matheis as Class C directors.","Approved amendment to increase authorized common stock from 200M to 300M shares.","Approved issuance of shares under Series B and B-1 Convertible Preferred Stock for Nasdaq Listing Rule 5635.","Ratified appointment of Marcum LLP as independent auditor for FY 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229595,"accession_number":"0001493152-24-024793","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Lucid Diagnostics receives Nasdaq bid price deficiency notice; 180 days to regain compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on June 21, 2024: closing bid price below $1 for 30 consecutive business days.","Must regain compliance by December 18, 2024 (180 calendar days).","To regain, closing bid must be at least $1 for 10 consecutive business days.","If not compliant, may request additional 180-day period or face delisting.","Stock continues trading under symbol LUCD with no immediate effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229594,"accession_number":"0001493152-24-021374","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Lucid Diagnostics reschedules annual meeting to July 23, new record date May 29","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting moved from June 20 to July 23, 2024 at 11:00 a.m. ET.","New record date for stockholders is May 29, 2024.","Rescheduling allows modification of proposals to be voted on.","Company will file revised proxy statement and mail new proxy materials.","Meeting location unchanged; virtual attendance via cstproxy.com."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229593,"accession_number":"0001493152-24-019020","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics Q1 revenue $1.0M; net loss $18.1M; EsoGuard volume up 10% sequentially","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["EsoGuard revenue $1.0M, flat vs Q4'23 but up 124% YoY.","GAAP net loss $18.1M ($0.40/share); non-GAAP adjusted loss $9.4M ($0.21/share).","Cash $24.8M at quarter end; subsequent $11.6M from Series B-1 offering.","MolDX pre-submission meeting scheduled July 17, 2024 for EsoGuard coverage.","EsoGuard test volume 2,420, +10% sequentially and +31% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":1001000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229592,"accession_number":"0001493152-24-018020","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["3.02","3.03","5.03","5.02","7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics closes $11.6M Series B-1 preferred offering; appoints Dennis Matheis to board","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds from combined Series B / B-1 offering total $29.8M; $11.6M from Series B-1, $18.6M from prior Series B.","Series B-1 convertible at $0.7228/share after 6-month anniversary; dividends in stock on first and second anniversary.","Dennis Matheis, President/CEO of Sentara Health ($13B revenue), appointed Class A director effective May 6, 2024.","Proceeds to extend working capital runway as company approaches critical reimbursement milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229591,"accession_number":"0001493152-24-017587","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Lucid Diagnostics announces positive NCI study: EsoGuard detects 89% of short-segment precancers","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EsoGuard showed 89% sensitivity for short-segment Barrett's esophagus (SSBE) in NCI-sponsored multicenter study.","Detected 100% of cancers; overall sensitivity/specificity 85% each; estimated NPV 98% and PPV 39%.","Study published in American Journal of Gastroenterology; investigators from Mayo Clinic, Johns Hopkins, Cleveland Clinic.","Company plans to seek Medicare coverage via MolDX pre-submission meeting and formal technical assessment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248126,"accession_number":"0001493152-24-009895","cik":1799011,"company_name":"Lucid Diagnostics Inc.","ticker":"LUCD","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["3.02","3.03","5.03","9.01"],"status":"ready","headline":"Lucid Diagnostics completes $18.16M Series B Preferred offering and exchange of Series A/A-1 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $18.16M: $12.495M from new subscriptions and $5.67M from Series A-1 sales immediately exchanged.","Series B Preferred convertible at $1.2444 per share; mandatory conversion on Mar 13, 2026 or if VWAP >$8 for 20 of 30 days.","Annual dividends: 20% of conversion shares on Mar 13, 2025 and Mar 13, 2026; accelerated on fundamental transactions.","Beneficial ownership limited to 4.99% (or 9.99% at holder election); primary market cap of 19.99% of outstanding common.","All outstanding Series A and A-1 Preferred exchanged; 44,285 Series B shares outstanding after close."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":212204784.89903843,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}